Original
Effect of Pre-existing Ischemic Heart Disease on 30-Days Mortality in COVID-19 Patients
Iqbal MH,1 *Moontaha H,2 Sarker BK,3 Paul MR,4 Chowdhury AW5
- Dr. Md. Hasan Iqbal, MBBS, Department of Cardiology, National Institute of Cardiovascular Disease (NICVD), Dhaka, Bangladesh
- *Dr. Hashiba Moontaha, MBBS, FCPS (Gynaecology& Obstetrics), Department of Gynaecology& Obstetrics, Dhaka Medical College &Hospital, Dhaka, Bangladesh;hashibapriom@gmail.com
- Dr. Bikash Kumar Sarker, Infectious Diseases Hospital, Mohakhali, Dhaka, Bangladesh
- Dr. Mira Rani Paul, Rajshahi Medical College Hospital, Rajshahi, Bangladesh.
- Professor Dr. Abdul Wadud Chowdhury, Director, National Institute of Cardiovascular Disease, Dhaka, Bangladesh.
*For correspondence
Abstract
Background: COVID-19 has emerged as a multisystem inflammatory disorder with significant cardiovascular implications. Patients with pre-existing cardiovascular conditions may be particularly vulnerable to severe outcomes, yet data from developing countries regarding the impact of pre-existing ischemic heart disease (IHD) on COVID-19 outcomes remains limited.
Objective: To investigate the effect of pre-existing ischemic heart disease on 30-day mortality in COVID-19 patients at a tertiary care hospital in Bangladesh.
Methods: This case-control study was conducted at Dhaka Medical College Hospital over twelve months, enrolling 120 RT-PCR-confirmed COVID-19 patients (60 with pre-existing IHD, 60 without IHD). Clinical characteristics, laboratory parameters, and treatment modalities were assessed. Outcomes included in-hospital mortality, complications, and 30-day mortality. Data analysis included chi-square tests, t-tests, and multivariable logistic regression.
Results: COVID-19 patients with pre-existing IHD showed significantly higher rates of critical disease (30.0% vs 11.6%, p=0.002), cardiac complications including acute myocardial infarction (45.0% vs 0%, p=0.001), and heart failure (28.3% vs 6.66%, p=0.001). The IHD group required more intensive care (71.6% vs 36.6%, p<0.001) and demonstrated higher in-hospital mortality (36.6% vs 10%, p<0.001) and 30-day mortality (60.0% vs 16.6%, p<0.001). After adjusting for confounders, pre-existing IHD independently predicted 30-day mortality (OR=7.25, 95% CI=2.17-24.23).
Conclusion: COVID-19 patients with pre-existing IHD experience significantly worse outcomes, including higher rates of complications and mortality. These findings emphasize the need for enhanced monitoring and aggressive management strategies for COVID-19 patients with pre-existing IHD in Bangladesh.
[Shaheed Syed Nazrul Islam Med Col J 2025, Jan; 10 (1):63-72]
DOI: https://www.doi.org/10.69699/ssnimcj2025v10i1s9
Keywords: COVID-19, Ischemic Heart Disease, Bangladesh, Mortality, Cardiovascular Complications